Literature DB >> 19963382

Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423.

Chris R Evelyn1, Jessica L Bell, Jenny G Ryu, Susan M Wade, Andrew Kocab, Nicole L Harzdorf, H D Showalter, Richard R Neubig, Scott D Larsen.   

Abstract

We recently identified bis(amide) CCG-1423 (1) as a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis. An initial structure-activity relationship study focusing on bioisosteric replacement of the amides and conformational restriction identified two compounds, 4g and 8, with improved selectivity for inhibition of RhoA/C-mediated gene transcription and attenuated cytotoxicity relative to 1. Both compounds were also capable of inhibiting cell invasion with equal efficacy to 1 but with less attendant cytotoxicity. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19963382      PMCID: PMC2818594          DOI: 10.1016/j.bmcl.2009.11.056

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  15 in total

1.  Actin dynamics control SRF activity by regulation of its coactivator MAL.

Authors:  Francesc Miralles; Guido Posern; Alexia-Ileana Zaromytidou; Richard Treisman
Journal:  Cell       Date:  2003-05-02       Impact factor: 41.582

2.  A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes.

Authors:  Vsevolod V Rostovtsev; Luke G Green; Valery V Fokin; K Barry Sharpless
Journal:  Angew Chem Int Ed Engl       Date:  2002-07-15       Impact factor: 15.336

Review 3.  Bioisosterism: a useful strategy for molecular modification and drug design.

Authors:  Lídia Moreira Lima; Eliezer J Barreiro
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

Review 4.  How structural features influence the biomembrane permeability of peptides.

Authors:  P S Burton; R A Conradi; N F Ho; A R Hilgers; R T Borchardt
Journal:  J Pharm Sci       Date:  1996-12       Impact factor: 3.534

5.  RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype.

Authors:  K L van Golen; Z F Wu; X T Qiao; L W Bao; S D Merajver
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

Review 6.  Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors.

Authors:  Tomi K Sawyer
Journal:  Expert Opin Investig Drugs       Date:  2004-01       Impact factor: 6.206

7.  Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis.

Authors:  Erik Sahai; Christopher J Marshall
Journal:  Nat Cell Biol       Date:  2003-08       Impact factor: 28.824

8.  A general and efficient copper catalyst for the amidation of aryl halides.

Authors:  Artis Klapars; Xiaohua Huang; Stephen L Buchwald
Journal:  J Am Chem Soc       Date:  2002-06-26       Impact factor: 15.419

9.  Megakaryoblastic leukemia 1, a potent transcriptional coactivator for serum response factor (SRF), is required for serum induction of SRF target genes.

Authors:  Bo Cen; Ahalya Selvaraj; Rebecca C Burgess; Johann K Hitzler; Zhigui Ma; Stephan W Morris; Ron Prywes
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

10.  Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis.

Authors:  Souhila Medjkane; Cristina Perez-Sanchez; Cedric Gaggioli; Erik Sahai; Richard Treisman
Journal:  Nat Cell Biol       Date:  2009-02-08       Impact factor: 28.824

View more
  36 in total

1.  Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases.

Authors:  Xun Shang; Fillipo Marchioni; Nisha Sipes; Chris R Evelyn; Moran Jerabek-Willemsen; Stefan Duhr; William Seibel; Matthew Wortman; Yi Zheng
Journal:  Chem Biol       Date:  2012-06-22

Review 2.  The role of HTS in drug discovery at the University of Michigan.

Authors:  Martha J Larsen; Scott D Larsen; Andrew Fribley; Jolanta Grembecka; Kristoff Homan; Anna Mapp; Andrew Haak; Zaneta Nikolovska-Coleska; Jeanne A Stuckey; Duxin Sun; David H Sherman
Journal:  Comb Chem High Throughput Screen       Date:  2014-03       Impact factor: 1.339

3.  Redox modification of nuclear actin by MICAL-2 regulates SRF signaling.

Authors:  Mark R Lundquist; Andrew J Storaska; Ting-Chun Liu; Scott D Larsen; Todd Evans; Richard R Neubig; Samie R Jaffrey
Journal:  Cell       Date:  2014-01-16       Impact factor: 41.582

Review 4.  Classification of scaffold-hopping approaches.

Authors:  Hongmao Sun; Gregory Tawa; Anders Wallqvist
Journal:  Drug Discov Today       Date:  2011-10-26       Impact factor: 7.851

5.  Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma.

Authors:  Kim M Hutchings; Erika M Lisabeth; Walajapet Rajeswaran; Michael W Wilson; Roderick J Sorenson; Phillip L Campbell; Jeffrey H Ruth; Asif Amin; Pei-Suen Tsou; Jeffrey R Leipprandt; Samuel R Olson; Bo Wen; Ting Zhao; Duxin Sun; Dinesh Khanna; David A Fox; Richard R Neubig; Scott D Larsen
Journal:  Bioorg Med Chem Lett       Date:  2017-03-10       Impact factor: 2.823

Review 6.  Transcriptional control of cardiac fibroblast plasticity.

Authors:  Janet K Lighthouse; Eric M Small
Journal:  J Mol Cell Cardiol       Date:  2015-12-22       Impact factor: 5.000

7.  Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β-induced fibrogenesis in human colonic myofibroblasts.

Authors:  Laura A Johnson; Eva S Rodansky; Andrew J Haak; Scott D Larsen; Richard R Neubig; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2014-01       Impact factor: 5.325

8.  Induction of megakaryocyte differentiation drives nuclear accumulation and transcriptional function of MKL1 via actin polymerization and RhoA activation.

Authors:  Elenoe C Smith; Alexandra M Teixeira; Rachel C Chen; Lin Wang; Yuan Gao; Katherine L Hahn; Diane S Krause
Journal:  Blood       Date:  2012-12-14       Impact factor: 22.113

9.  Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents.

Authors:  Jessica L Bell; Andrew J Haak; Susan M Wade; Paul D Kirchhoff; Richard R Neubig; Scott D Larsen
Journal:  Bioorg Med Chem Lett       Date:  2013-05-07       Impact factor: 2.823

Review 10.  Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription.

Authors:  Pei-Suen Tsou; Andrew J Haak; Dinesh Khanna; Richard R Neubig
Journal:  Am J Physiol Cell Physiol       Date:  2014-04-16       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.